Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women

European Journal of Clinical Investigation

Volumn 45, Issue 2, 2015, Pages 144-149

  Catalano, Antonino ^a   Morabito, Nancy ^a   Basile, Giorgio ^a   Cucinotta, Domenico ^a   Lasco, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Atorvastatin; Calcifediol; Lipids; Osteopenia; Postmenopausal; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; CALCIFEDIOL; COLECALCIFEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; 25-HYDROXYVITAMIN D; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; VITAMIN; VITAMIN D;

ADULT; ARTICLE; BODY MASS; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; BONE DISEASES, METABOLIC; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; LIPID METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

ADMINISTRATION, ORAL; BONE DISEASES, METABOLIC; CALCIFEDIOL; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; MIDDLE AGED; POSTMENOPAUSE; PYRROLES; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84921551092     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12390     Document Type: Article

References (39)

1. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
4. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
5. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-41.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
7. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
8. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008;102:1540-4.
9. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B et al. Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-9.
10. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-11.
11. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174-80.
12. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-30.
13. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
14. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-7.
15. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 2011;31:48-54.
16. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007;167:1159-65.
17. Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010;59:242-8.
18. Fraser A, Williams D, Lawlor DA. Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001-2006). PLoS ONE 2010;5:e13882.
19. Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G. High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. Eur J Clin Nutr 2010;64:1457-64.
20. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
21. Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs 2007;67(Suppl 1):2.
22. Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol 2010;2010:320721.
23. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-5.
24. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome. Clin Chem 2010;56:1696-700.
25. Grimes DS. Are statins analogues of vitamin D? Lancet 2006;368:83-6.
26. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
27. Ockene IS, Chiriboga DE, Stanek EJ 3rd, Harmatz MG, Nicolosi R, Saperia G et al. Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med 2004;164:863-70.
28. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation 2012;126:270-7.
29. Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res 1989;30:379-86.
30. Qin XF, Zhao LS, Chen WR, Yin DW, Wang H. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial. Clin Nutr 2014; pii: S0261-5614(14)00125-3. doi: 10.1016/j.clnu.2014.04.017. [Epub ahead of print]
31. Schnatz PF, Jiang X, Vila-Wright S, Aragaki AK, Nudy M, O'Sullivan DM et al. Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. Menopause. 2014;21:823-33.
32. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha, 25-dihydroxy vitamin D3. Mol Pharmacol 2001;60:1399-406.
33. Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010;285:14486-94.
34. Kane L, Moore K, Lütjohann D, Bikle D, Schwartz JB. Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. J Clin Endocrinol Metab 2013;98:4400-9.
35. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M et al. STATIN-D Study: comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D. Cardiovasc Ther 2011;29:146-52.
36. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009;94:4023-30.
37. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
38. Jetter A, Egli A, Dawson-Hughes B, Staehelin HB, Stoecklin E, Goessl R et al. Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone 2014;59:14-9.
39. Brandi ML, Minisola S. Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. Curr Med Res Opin 2013;29:1565-72.